<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335192</url>
  </required_header>
  <id_info>
    <org_study_id>INTRANUCS</org_study_id>
    <secondary_id>2004-000948-25</secondary_id>
    <nct_id>NCT00335192</nct_id>
  </id_info>
  <brief_title>To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir</brief_title>
  <official_title>Determination of Plasma and Intracellular Levels of Nucleoside Reverse Transcriptase Inhibitors (NRTI) and of Nucleotide Analog Tenofovir Disoproxil Fumarate (TDF) in Patients Treated With Abacavir and/or Lamivudine Given With or Without TDF.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if there are pharmacokinetic interactions between&#xD;
      the NRTI 3TC and ABV, and the TDF nucleotide. For this purpose, the intracellular and plasma&#xD;
      levels of 3TC and ABV will be compared in patients given these nucleosides with TDF and 30&#xD;
      days after the interruption of the TDF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is clear evidence of pharmacokinetic interaction between ddI+TDF. However, the&#xD;
      interaction between TDF and other NRTIs, mainly at intracellular level, has not been so well&#xD;
      studied.&#xD;
&#xD;
      Since all the NRTIs are anabolized at intracellular level by numerous kinases, and are&#xD;
      transported by passive carrier systems, the interaction may be between TDF and other NRTIs.&#xD;
&#xD;
      This study aims to investigate the pharmacokinetic interactions between the TDF and the&#xD;
      nucleosides abacavir (ABV) and lamivudine (3TC) at plasma and intracellular level.&#xD;
&#xD;
      With this objective, intracellular and plasma levels will be analysed in a group of patients&#xD;
      that receive the combinations 3TC +TDF, ABV+TDF and 3TC+ABV+TDF together with lopinavir/rtv&#xD;
      or nevirapine. Subsequently, in a second phase of the study, in the group of patients given&#xD;
      ABV and/or 3TC + TDF + lopinavir/rtv, the pharmacokinetic determinations will be repeated&#xD;
      after a 4-week interruption of the TDF .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint will be the variation between the intracellular levels of 3TC and ABC before and after the interruption of the treatment with TDF</measure>
    <time_frame>At baseline and week 4.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variations between the plasma levels of 3TC and ABC before and after interruption of the treatment with TDF.</measure>
    <time_frame>at baseline and week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the intracellular and plasma levels of 3TC, ABC and TDF.</measure>
    <time_frame>at baseline and week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the intracellular levels of TDF following the withdrawal of the drug.</measure>
    <time_frame>At week 4.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: 3TC + TDF + NVP or LPV/rtv&#xD;
Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + LPV/rtv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: ABV + TDF + NVP or LPV/rtv&#xD;
Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: ABV + LPV/rtv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: 3TC + ABV + TDF + NVP or LPV/rtv&#xD;
Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + ABV + LPV/rtv</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks</intervention_name>
    <description>3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Epivir</other_name>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks</intervention_name>
    <description>ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Ziagen</other_name>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks</intervention_name>
    <description>3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Epivir</other_name>
    <other_name>Ziagen</other_name>
    <other_name>Kaletra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV+ patients aged above 18 years.&#xD;
&#xD;
          2. Undetectable HIV viral load in the last determination&#xD;
&#xD;
          3. Patients capable of correct compliance according to clinical criteria.&#xD;
&#xD;
          4. Patients on triple HAART therapy for the previous 3 months including 3TC and/or ABV&#xD;
             and TDF, with a PI (Lopinavir/ritonavir) or an NNRTI (Nevirapine)&#xD;
&#xD;
          5. Women may not be of fertile age (defined as at least one year from menopause or&#xD;
             undergoing any surgical sterilisation technique), or must undertake to use a barrier&#xD;
             contraceptive method during the study.&#xD;
&#xD;
          6. Ability to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Incorrect therapeutic compliance over the four weeks before the beginning of the&#xD;
             study.&#xD;
&#xD;
          2. Interruption or withdrawal from therapy during follow-up.&#xD;
&#xD;
          3. Concomitant treatment with any drug which according to the clinician's criterion may&#xD;
             interact with the investigational antiretrovirals, such as other antiretrovirals.&#xD;
&#xD;
          4. Triple HAART therapy including Nevirapine (for phase II)&#xD;
&#xD;
          5. Documented or suspected resistance to ABV, 3TC or lopinavir/rtv (for phase II).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonaventura Clotet, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LLuita contra la Sida Foundation-HIV Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>June 8, 2006</study_first_submitted>
  <study_first_submitted_qc>June 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2006</study_first_posted>
  <last_update_submitted>September 5, 2008</last_update_submitted>
  <last_update_submitted_qc>September 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>LLuita Sida Foundation</name_title>
    <organization>LLuita Sida Foundation</organization>
  </responsible_party>
  <keyword>Intracellular concentrations</keyword>
  <keyword>Plasma concentration</keyword>
  <keyword>Abacavir</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Lamivudine (3TC)</keyword>
  <keyword>Pharmacokinetic interactions</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

